Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03206931

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Solid Tumors Harboring NTRK Fusion Clinical Trial

Official title:
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.

Clinical Trial Summary

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Solid Tumors Harboring NTRK Fusion
Clinical Trial Details
NCT number NCT03206931
Study type Expanded Access
Source Bayer
Contact
Status No longer available
Phase
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02576431 - A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Phase 2
Completed NCT02122913 - A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Phase 1
Completed NCT03215511 - A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer Phase 1
Completed NCT04275960 - Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body Phase 1
Completed NCT04771390 - Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants Phase 1
Completed NCT05192642 - A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
Active, not recruiting NCT02637687 - A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Phase 1/Phase 2